Now 28M .0008 x 20M left at .0009 - 71M volume in 20
Now 28M .0008 x 20M left at .0009 - 71M volume in 20 minutes.
This is just the first of 3 x PRs due imminently from recent Tweets - and of course we have all the other ongoing catalysts from multiple lines of business development - of which the biggest is currently The Wild Geese movie remake with more A-list actors to be announced.
VALIANT EAGLE INC. (PSRU) Stock Research Links
"Per Ardua Ad Astra" - "Through Adversity To The Stars"
A very apposite motto for those who trade successfully in the OTC market..
All posts are my opinion - trade at your own risk.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Triumph Financial Plans Fourth Quarter Earnings Release Triumph Financial, Inc. (Nasdaq: TFIN) recently announced its anticipation for the release of fourth quarter financial results. This event is scheduled to take place after the market closes on an upcoming Wednesday. Along with the financial report, the company will provide management commentary for stakeholders and...
Continue Reading
The Nuts and Bolts of Progress Monitoring You've got a situation in Leominster where parents are trying to make sense of ABA therapy's impact on their kids. Rob Shapiro, a big name in the ABA world, breaks it all down in a HelloNation article. We're talking about precise data collection being the backbone of measuring progress in ABA therapy. This ain't no place for...
Continue Reading
Public Disclosure Regarding Dowlais Group's Trading Activity FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code 1. KEY INFORMATION (a) Name of exempt principal trader: Investec Bank plc (b) Name of offeror/offeree in relation to whose r
Continue Reading
OFS Credit Company Delivers Strong Q4 2024 Financial Results OFS Credit Company, Inc. (NASDAQ: OCCI), a notable investment firm focusing on collateralized loan obligation (CLO) equity and debt securities, has announced its financial performance for the fiscal quarter ending October 31, 2024. This report outlines the company’s significant financial growth and strategic...
Continue Reading
HBI-8000 and Nivolumab: A New Era in Melanoma Treatment Recent findings highlight the potential of HBI-8000 in combination with nivolumab, suggesting a transformative approach in the treatment of advanced melanoma. This promising combination will be discussed in detail at an upcoming prestigious annual meeting focused on advancements in immunotherapy. Innovative Solutions...
Continue Reading
